Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

APLS

Apellis Pharmaceuticals Inc

Jan 17 • 04:00PM ET

29.93

Dollar change +0.20
Percentage change 0.69	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN REGN SRPT MRNA BMRN EXEL VRTX PBYI UTHR KURA

| Held by: VTI VB XBI VXF VBK IBB IWP SCHA IWF IWR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.04	Insider Own	18.35%	Shs Outstand	122.07M	Perf Week	9.09%
Market Cap	3.72B	Forward P/E	-	EPS next Y	-0.88	Insider Trans	-0.31%	Shs Float	101.51M	Perf Month	-11.07%
Income	-250.10M	PEG	-	EPS next Q	-0.37	Inst Own	90.87%	Short Float	21.16%	Perf Quarter	7.10%
Sales	715.22M	P/S	5.21	EPS this Y	62.44%	Inst Trans	2.31%	Short Ratio	6.86	Perf Half Y	-21.12%
Book/sh	1.94	P/B	15.41	EPS next Y	47.17%	ROA	-29.08%	Short Interest	21.48M	Perf Year	-54.59%
Cash/sh	3.20	P/C	9.35	EPS next 5Y	-	ROE	-106.56%	52W Range	24.34 - 71.90	Perf YTD	-6.19%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-13.70%	ROI	-35.69%	52W High	-58.37%	Beta	0.96
Dividend TTM	-	Quick Ratio	3.73	Sales past 5Y	91.42%	Gross Margin	86.28%	52W Low	22.99%	ATR (14)	1.71
Dividend Ex-Date	-	Current Ratio	4.36	EPS Y/Y TTM	61.20%	Oper. Margin	-31.23%	RSI (14)	43.96	Volatility	5.16% 4.68%
Employees	706	Debt/Eq	1.98	Sales Y/Y TTM	162.10%	Profit Margin	-34.97%	Recom	1.74	Target Price	45.85
Option/Short	Yes / Yes	LT Debt/Eq	1.96	EPS Q/Q	60.34%	Payout	-	Rel Volume	0.48	Prev Close	29.73
Sales Surprise	-1.59%	EPS Surprise	-55.99%	Sales Q/Q	78.29%	Earnings	Nov 05 BMO	Avg Volume	3.13M	Price	29.93
SMA20	-6.07%	SMA50	-5.10%	SMA200	-18.80%	Trades		Volume	1,510,920	Change	0.69%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-17-24	Downgrade	Goldman	Buy → Neutral	$36
Nov-21-24	Initiated	Morgan Stanley	Equal-Weight	$31
Oct-25-24	Initiated	RBC Capital Mkts	Sector Perform	$25
Oct-16-24	Initiated	William Blair	Outperform
Oct-16-24	Initiated	Scotiabank	Sector Outperform
May-31-24	Initiated	Piper Sandler	Neutral	$46
Feb-05-24	Upgrade	Jefferies	Hold → Buy	$68 → $80
Dec-14-23	Downgrade	Wells Fargo	Overweight → Equal Weight
Nov-09-23	Initiated	Goldman	Buy	$74
Nov-02-23	Initiated	Mizuho	Neutral	$42
Oct-06-23	Upgrade	JP Morgan	Neutral → Overweight	$60 → $81
Sep-15-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$34 → $64
Aug-29-23	Reiterated	Citigroup	Buy	$45 → $54
Aug-03-23	Downgrade	JP Morgan	Overweight → Neutral	$72 → $60
Aug-01-23	Downgrade	BofA Securities	Buy → Neutral	$114 → $40
Jan-03-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$83 → $58
Nov-10-22	Downgrade	Jefferies	Buy → Hold	$70 → $40
Jul-19-22	Initiated	H.C. Wainwright	Buy	$75
Jun-17-22	Resumed	Stifel	Buy	$60
Apr-14-22	Downgrade	ROTH Capital	Neutral → Sell	$40

Show Previous Ratings

Jan-13-25 09:00AM	Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-10-25 07:00AM	Apellis Announces Keli Walbert to Join the Board of Directors (GlobeNewswire) -16.85%
Jan-07-25 04:05PM	Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-06-25 07:00AM	Apellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-12-24 09:35AM	Should You Hold Apellis Pharmaceuticals (APLS)? (Insider Monkey)
04:05PM	Loading…
Dec-06-24 04:05PM	Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-05-24 11:30AM	Why Is Apellis Pharmaceuticals (APLS) Up 18.4% Since Last Earnings Report? (Zacks)
Nov-27-24 07:00AM	Apellis Pharmaceuticals to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-12-24 07:00AM	Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-07-24 06:31AM	Apellis price target lowered to $30 from $43 at Wells Fargo (TipRanks)
06:25AM	Apellis price target lowered to $47 from $61 at BofA (TipRanks)
Nov-06-24 02:10AM	Apellis Pharmaceuticals Inc (APLS) Q3 2024 Earnings Call Highlights: Revenue Surge and ... (GuruFocus.com)
Nov-05-24 04:47PM	Why Apellis Pharmaceuticals Stock Was Tumbling on Tuesday (Motley Fool)
09:30AM	Apellis Pharmaceuticals (APLS) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
09:24AM	Apellis Pharmaceuticals Dives On Worse-Than-Expected Syfovre Sales (Investor's Business Daily)
08:20AM	Loading…
08:20AM	Apellis Pharmaceuticals, Inc. (APLS) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:05AM	Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-04-24 07:04AM	Apellis Pharmaceuticals Inc (APLS) Q3 2024 Earnings Report Preview: What to Look For (GuruFocus.com)
Oct-30-24 06:00AM	Axonis Therapeutics Announces $115 Million Series A Financing (PR Newswire)
Oct-29-24 10:01AM	Will Apellis Pharmaceuticals, Inc. (APLS) Report Negative Earnings Next Week? What You Should Know (Zacks)
05:51AM	1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst (Motley Fool)
Oct-28-24 08:40AM	Apellis, Sobi announced results from Phase 3 VALIANT study (TipRanks)
Oct-26-24 02:00PM	Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN (GlobeNewswire)
Oct-22-24 07:00AM	Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-16-24 02:56PM	Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch (Benzinga)
07:00AM	Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN (GlobeNewswire)
Oct-04-24 04:05PM	Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-03-24 10:19AM	Should You Hold Apellis Pharmaceuticals (APLS)? (Insider Monkey)
Sep-25-24 07:00AM	Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day (GlobeNewswire)
Sep-20-24 04:10PM	Apellis Stock Hammered After Eye Drug Gets A Third European Rejection (Investor's Business Daily) -11.49%
06:17AM	Loading…
06:17AM	Apellis eye drug again turned back in Europe (BioPharma Dive)
05:00AM	Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination (GlobeNewswire)
Sep-14-24 07:36PM	Apellis Pharmaceuticals, Inc. (APLS): Among Hedge Funds Top Biotech Stock Picks (Insider Monkey)
Sep-06-24 04:05PM	Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-04-24 11:57PM	Apellis Pharmaceuticals, Inc. (APLS): Among the Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Sep-02-24 06:05PM	10 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-29-24 07:00AM	Apellis Pharmaceuticals to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-13-24 07:15AM	Wedbush Just Raised its Price Target on These 7 Stocks: August 12, 2024 (InvestorPlace)
Aug-09-24 04:32AM	Sobi and Apellis report positive topline results from Phase III pegcetacoplan study (Clinical Trials Arena)
Aug-08-24 07:57AM	Apellis plans FDA filing after drug success in kidney trial (BioPharma Dive) +12.12%
07:32AM	Sobi and Apellis announce positive topline results from phase 3 VALIANT study of pegcetacoplan in C3G and primary IC-MPGN (PR Newswire)
07:00AM	Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN (GlobeNewswire)
Aug-06-24 04:05PM	Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-01-24 10:01AM	Apellis (APLS) Q2 Earnings Beat, Syfovre Sales Drive Revenues (Zacks) -9.09%
09:30AM	Compared to Estimates, Apellis Pharmaceuticals (APLS) Q2 Earnings: A Look at Key Metrics (Zacks)
08:15AM	Apellis Pharmaceuticals, Inc. (APLS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:05AM	Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-25-24 10:01AM	Apellis Pharmaceuticals, Inc. (APLS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Jul-18-24 07:00AM	Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-09-24 07:00AM	Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting (GlobeNewswire)
Jul-05-24 08:41AM	Apellis' (APLS) Syfovre Boost Sales, Regulatory Setbacks a Woe (Zacks)
Jul-01-24 08:44AM	Apellis (APLS) Falls on Second Negative CHMP Opinion for GA Drug (Zacks) -5.40%
Jun-28-24 06:57AM	Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU (GlobeNewswire) -7.61%
Jun-11-24 09:48AM	Apellis (APLS) Up on Upbeat GA Data From Long-Term Syfovre Study (Zacks)
Jun-10-24 07:00AM	SYFOVRE (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA) (GlobeNewswire)
Jun-06-24 11:31AM	Why Is Apellis Pharmaceuticals (APLS) Down 1.9% Since Last Earnings Report? (Zacks)
Jun-05-24 07:00AM	Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-27-24 12:33PM	Apellis (APLS) Posts Upbeat One-Year Kidney Diseases Study Data (Zacks)
04:25AM	Apellis and Sobi report data from Phase II C3 glomerulopathy trial (Clinical Trials Arena)
May-24-24 10:00AM	Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress (GlobeNewswire)
May-14-24 10:02AM	Apellis Pharmaceuticals Enters Into Senior Secured Credit Facility With Sixth Street (MT Newswires)
08:00AM	Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street (GlobeNewswire)
May-09-24 05:22PM	Apellis Pharmaceuticals Insider Sold Shares Worth $3,341,848, According to a Recent SEC Filing (MT Newswires)
May-08-24 12:26PM	Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:13AM	Apellis Pharmaceuticals Inc (APLS) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue ... (GuruFocus.com)
May-07-24 11:19AM	Apellis' (APLS) Q1 Earnings Match Estimates, Revenues Beat (Zacks) -10.06%
09:30AM	Apellis Pharmaceuticals (APLS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:15AM	Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:56AM	Apellis Pharmaceuticals Q1 Net Loss Narrows, Revenue Rises (MT Newswires)
07:05AM	Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-06-24 07:00AM	Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference (GlobeNewswire)
May-01-24 07:00AM	Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting (GlobeNewswire)
Apr-30-24 10:00AM	Will Apellis Pharmaceuticals, Inc. (APLS) Report Negative Earnings Next Week? What You Should Know (Zacks) -7.63%
Apr-26-24 10:30AM	Apellis Pharmaceuticals Says EMA Moves Pegcetacoplan Application to Last Phase of Initial Assessment (MT Newswires)
07:15AM	Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA) (GlobeNewswire)
Apr-23-24 07:00AM	Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results (GlobeNewswire)
Apr-04-24 04:05PM	Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-01-24 07:00AM	Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-28-24 11:30AM	Apellis Pharmaceuticals (APLS) Down 8.7% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-19-24 07:01PM	Insider Sell: Chief Business & Strategy Officer Mark Delong Sells 9,913 Shares of Apellis ... (GuruFocus.com)
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-14-24 07:02PM	Apellis Pharmaceuticals Inc (APLS) CTO Nur Nicholson Sells 11,220 Shares (GuruFocus.com)
Mar-11-24 07:02PM	Apellis Pharmaceuticals Inc's Chief Scientific Officer Pascal Deschatelets Sells 69,107 Shares (GuruFocus.com)
07:00AM	Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor (GlobeNewswire)
Mar-06-24 04:05PM	Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-28-24 09:35AM	Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q4 2023 Earnings Call Transcript (Insider Monkey) -7.64%
09:07AM	Apellis (APLS) Q4 Earnings Miss, Revenues Meet Estimates (Zacks)
Feb-27-24 09:30AM	Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
08:20AM	Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:51AM	Apellis Pharmaceuticals Inc (APLS) Reports Robust Revenue Growth in 2023 (GuruFocus.com)
07:05AM	Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-26-24 07:00AM	Apellis Pharmaceuticals to Present at Upcoming Investor Conferences (GlobeNewswire)
Feb-23-24 09:27AM	Why Apellis (APLS) Might Surprise This Earnings Season (Zacks)
Feb-20-24 12:00PM	Apellis Pharmaceuticals, Inc. (APLS) Upgraded to Buy: Here's What You Should Know (Zacks)
07:00AM	Apellis Pharmaceuticals to Host Conference Call on February 27, 2024, to Discuss Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-14-24 09:40AM	Has Apellis Pharmaceuticals (APLS) Outpaced Other Medical Stocks This Year? (Zacks)
Feb-13-24 10:00AM	Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks)
Feb-06-24 04:05PM	Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-29-24 08:48AM	Apellis (APLS) Down on Negative CHMP Opinion for Pegcetacoplan (Zacks)
Jan-26-24 07:06AM	Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union and Plans to Seek Re-Examination of Application (GlobeNewswire)

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Townsend Adam J.	Officer	Jan 17 '25	Proposed Sale	29.96	2,201	65,938		Jan 17 04:38 PM
Deschatelets Pascal	Officer	Jan 17 '25	Proposed Sale	29.96	750	22,469		Jan 17 04:35 PM
Nicholson Nur	Officer	Jan 17 '25	Proposed Sale	29.96	2,145	64,260		Jan 17 04:32 PM
Chopas James George	Officer	Jan 17 '25	Proposed Sale	29.96	715	21,420		Jan 17 04:29 PM
Francois Cedric	Officer	Jan 17 '25	Proposed Sale	29.96	6,007	179,959		Jan 17 04:27 PM
Watson David O.	Officer	Jan 17 '25	Proposed Sale	29.96	2,201	65,938		Jan 17 04:20 PM
Baumal Caroline	Officer	Jan 17 '25	Proposed Sale	29.96	1,853	55,513		Jan 17 04:18 PM
Lewis Karen	Officer	Jan 17 '25	Proposed Sale	29.96	1,241	37,178		Jan 17 04:16 PM
Sullivan Timothy Eugene	Officer	Jan 17 '25	Proposed Sale	29.96	1,730	51,828		Jan 17 04:16 PM
DeLong Mark Jeffrey	Officer	Jan 17 '25	Proposed Sale	29.96	1,235	36,998		Jan 17 04:14 PM
Watson David O.	General Counsel	Jan 13 '25	Sale	28.70	4,965	142,506	107,756	Jan 14 04:30 PM
Townsend Adam J.	Chief Commercial Officer	Jan 13 '25	Sale	28.70	2,685	77,065	90,269	Jan 14 04:29 PM
Sullivan Timothy Eugene	Chief Financial Officer	Jan 13 '25	Sale	28.70	2,170	62,284	88,100	Jan 14 04:25 PM
Nicholson Nur	Chief Technical Officer	Jan 13 '25	Sale	28.70	2,632	75,544	54,156	Jan 14 04:22 PM
Lewis Karen	Chief People Officer	Jan 13 '25	Sale	28.70	1,599	45,895	45,099	Jan 14 04:20 PM
Francois Cedric	Chief Executive Officer	Jan 13 '25	Sale	28.70	6,247	179,302	307,415	Jan 14 04:18 PM
Eisele Jeffrey	Chief Development Officer	Jan 13 '25	Sale	28.70	264	7,577	56,881	Jan 14 04:15 PM
Deschatelets Pascal	Chief Scientific Officer	Jan 13 '25	Sale	28.70	2,288	65,670	1,138,195	Jan 14 04:14 PM
DeLong Mark Jeffrey	Chief Business & Strat Officer	Jan 13 '25	Sale	28.70	1,599	45,895	58,796	Jan 14 04:10 PM
Chopas James George	VP/Chief Accounting Officer	Jan 13 '25	Sale	28.70	783	22,474	37,358	Jan 14 04:09 PM
Lewis Karen	Officer	Jan 13 '25	Proposed Sale	28.70	1,627	46,689		Jan 13 06:15 PM
Sullivan Timothy Eugene	Officer	Jan 13 '25	Proposed Sale	28.70	2,209	63,390		Jan 13 06:13 PM
Townsend Adam J.	Officer	Jan 13 '25	Proposed Sale	28.70	2,734	78,456		Jan 13 06:09 PM
Eisele Jeffrey	Officer	Jan 13 '25	Proposed Sale	28.70	264	7,576		Jan 13 06:07 PM
Nicholson Nur	Officer	Jan 13 '25	Proposed Sale	28.70	2,681	76,935		Jan 13 06:05 PM
Watson David O.	Officer	Jan 13 '25	Proposed Sale	28.70	5,056	145,088		Jan 13 06:02 PM
Francois Cedric	Officer	Jan 13 '25	Proposed Sale	28.70	6,357	182,422		Jan 13 06:02 PM
Deschatelets Pascal	Officer	Jan 13 '25	Proposed Sale	28.70	2,331	66,891		Jan 13 06:00 PM
DeLong Mark Jeffrey	Officer	Jan 13 '25	Proposed Sale	28.70	1,627	46,689		Jan 13 05:56 PM
Chopas James George	Officer	Jan 13 '25	Proposed Sale	28.70	798	22,900		Jan 13 05:55 PM
Baumal Caroline	Chief Medical Officer	Jan 06 '25	Sale	33.81	2,816	95,215	55,560	Jan 08 04:03 PM
Baumal Caroline	Officer	Jan 06 '25	Proposed Sale	33.81	2,816	95,213		Jan 06 03:17 PM
Eisele Jeffrey	Chief Development Officer	Dec 23 '24	Sale	33.09	63	2,085	57,145	Dec 27 04:06 PM
Eisele Jeffrey	Officer	Dec 23 '24	Proposed Sale	33.09	63	2,085		Dec 23 03:09 PM
Watson David O.	General Counsel	Dec 11 '24	Sale	34.23	5,000	171,175	112,721	Dec 13 04:15 PM
DAVID OSBORNE WATSON	Officer	Dec 11 '24	Proposed Sale	34.23	5,000	171,175		Dec 11 04:48 PM
Dunlop A. Sinclair	Director	Sep 23 '24	Option Exercise	13.19	4,600	60,674	152,126	Sep 24 04:20 PM
Dunlop A. Sinclair	Director	Sep 16 '24	Sale	36.23	37,000	1,340,597	100,000	Sep 17 05:21 PM
Chopas James George	VP/Chief Accounting Officer	Sep 16 '24	Sale	36.21	192	6,952	38,141	Sep 17 04:08 PM
Chopas James George	Officer	Sep 16 '24	Proposed Sale	36.21	192	6,952		Sep 16 03:22 PM
Chopas James George	VP/Chief Accounting Officer	Sep 03 '24	Sale	39.49	550	21,720	38,333	Sep 04 04:07 PM
Chopas James George	Officer	Sep 03 '24	Proposed Sale	39.49	550	21,720		Sep 03 03:16 PM
DeLong Mark Jeffrey	Chief Business & Strat Officer	Aug 12 '24	Option Exercise	13.85	5,201	72,034	60,395	Aug 13 04:13 PM
Dunlop A. Sinclair	Director	Jun 28 '24	Option Exercise	13.19	900	11,871	134,418	Jul 01 04:02 PM
Dunlop A. Sinclair	Director	Jun 21 '24	Sale	39.24	37,000	1,451,835	136,998	Jun 21 07:34 PM
Deschatelets Pascal	Chief Scientific Officer	May 20 '24	Option Exercise	3.76	24,500	92,120	1,140,483	May 21 04:03 PM
Deschatelets Pascal	Chief Scientific Officer	May 08 '24	Option Exercise	4.31	78,907	340,089	1,194,890	May 09 05:15 PM
Deschatelets Pascal	Chief Scientific Officer	May 08 '24	Sale	42.35	78,907	3,341,848	1,115,983	May 09 05:15 PM
Dunlop A. Sinclair	Director	Apr 12 '24	Option Exercise	13.19	1,500	19,785	133,518	Apr 15 04:09 PM
Deschatelets Pascal	Chief Scientific Officer	Apr 08 '24	Option Exercise	3.76	69,107	259,842	1,185,090	Apr 09 04:25 PM
Deschatelets Pascal	Chief Scientific Officer	Apr 08 '24	Sale	54.17	69,107	3,743,605	1,115,983	Apr 09 04:25 PM
Sullivan Timothy Eugene	Chief Financial Officer	Apr 01 '24	Option Exercise	10.03	4,000	40,120	97,338	Apr 02 04:06 PM
Sullivan Timothy Eugene	Chief Financial Officer	Apr 01 '24	Sale	58.66	4,000	234,640	93,338	Apr 02 04:06 PM
Dunlop A. Sinclair	Director	Mar 19 '24	Sale	57.18	18,681	1,068,161	173,998	Mar 20 05:18 PM
DeLong Mark Jeffrey	Chief Business & Strat Officer	Mar 18 '24	Sale	56.90	9,913	564,050	54,693	Mar 19 04:03 PM
Chopas James George	VP/Chief Accounting Officer	Mar 15 '24	Sale	56.46	184	10,389	38,883	Mar 18 04:19 PM
Nicholson Nur	Chief Technical Officer	Mar 13 '24	Sale	57.56	11,220	645,838	56,287	Mar 14 04:17 PM
Deschatelets Pascal	Chief Scientific Officer	Mar 08 '24	Option Exercise	3.67	69,107	253,623	1,185,090	Mar 11 04:08 PM
Deschatelets Pascal	Chief Scientific Officer	Mar 08 '24	Sale	62.19	69,107	4,297,549	1,115,983	Mar 11 04:08 PM
Watson David O.	General Counsel	Mar 06 '24	Option Exercise	13.85	3,762	52,104	107,152	Mar 08 07:45 AM
Francois Cedric	Chief Executive Officer	Mar 01 '24	Option Exercise	4.20	250,000	1,050,000	563,662	Mar 05 04:07 PM
Francois Cedric	Chief Executive Officer	Mar 01 '24	Sale	64.11	250,000	16,028,706	313,662	Mar 05 04:07 PM
Sullivan Timothy Eugene	Chief Financial Officer	Mar 01 '24	Option Exercise	10.03	6,000	60,180	99,338	Mar 05 04:04 PM
Sullivan Timothy Eugene	Chief Financial Officer	Mar 01 '24	Sale	63.22	6,000	379,340	93,338	Mar 05 04:04 PM
Watson David O.	General Counsel	Feb 12 '24	Sale	67.77	781	52,926	103,390	Feb 13 05:06 PM
Townsend Adam J.	Chief Commercial Officer	Feb 12 '24	Sale	67.77	1,148	77,796	92,453	Feb 13 05:05 PM
Sullivan Timothy Eugene	Chief Financial Officer	Feb 12 '24	Sale	67.77	1,431	96,974	93,338	Feb 13 04:59 PM
Francois Cedric	Chief Executive Officer	Feb 12 '24	Sale	67.77	3,962	268,492	313,662	Feb 13 04:49 PM
Deschatelets Pascal	Chief Scientific Officer	Feb 12 '24	Sale	67.77	1,148	77,796	1,115,983	Feb 13 04:43 PM
DeLong Mark Jeffrey	Chief Business & Strat Officer	Feb 12 '24	Sale	67.77	597	40,457	64,606	Feb 13 04:38 PM
Watson David O.	General Counsel	Jan 29 '24	Sale	64.14	906	58,109	104,171	Jan 31 04:38 PM
Townsend Adam J.	Chief Commercial Officer	Jan 29 '24	Sale	64.14	906	58,109	93,601	Jan 31 04:36 PM
Sullivan Timothy Eugene	Chief Financial Officer	Jan 29 '24	Sale	64.14	906	58,109	94,769	Jan 31 04:34 PM
Nicholson Nur	Chief Technical Officer	Jan 29 '24	Sale	64.14	835	53,555	67,507	Jan 31 04:31 PM
Lewis Karen	Chief People Officer	Jan 30 '24	Sale	65.53	883	57,863	46,387	Jan 31 04:28 PM
Lewis Karen	Chief People Officer	Jan 29 '24	Sale	64.14	367	23,539	47,270	Jan 31 04:28 PM
Francois Cedric	Chief Executive Officer	Jan 29 '24	Sale	64.14	2,843	182,345	317,624	Jan 31 04:26 PM
Eisele Jeffrey	Chief Development Officer	Jan 30 '24	Sale	65.53	971	63,630	57,208	Jan 31 04:23 PM
Eisele Jeffrey	Chief Development Officer	Jan 29 '24	Sale	64.14	279	17,895	58,179	Jan 31 04:23 PM
Deschatelets Pascal	Chief Scientific Officer	Jan 29 '24	Sale	64.14	874	56,057	1,117,131	Jan 31 04:21 PM
DeLong Mark Jeffrey	Chief Business & Strat Officer	Jan 29 '24	Sale	64.14	367	23,539	65,203	Jan 31 04:18 PM
Lewis Karen	Chief People Officer	Jan 23 '24	Sale	63.69	4,286	272,975	47,637	Jan 24 04:06 PM
Eisele Jeffrey	Chief Development Officer	Jan 23 '24	Sale	63.69	7,378	469,905	58,458	Jan 24 04:03 PM
Francois Cedric	Chief Executive Officer	Jan 22 '24	Sale	65.00	13,431	872,961	320,467	Jan 23 07:28 PM
Watson David O.	General Counsel	Jan 22 '24	Sale	65.00	4,184	271,943	105,077	Jan 23 06:17 PM
Townsend Adam J.	Chief Commercial Officer	Jan 22 '24	Sale	65.00	3,413	221,831	94,507	Jan 23 06:15 PM
Sullivan Timothy Eugene	Chief Financial Officer	Jan 22 '24	Sale	65.00	3,551	230,801	95,675	Jan 23 06:13 PM
Nicholson Nur	Chief Technical Officer	Jan 22 '24	Sale	65.00	2,593	168,535	68,342	Jan 23 06:11 PM
Lewis Karen	Chief People Officer	Jan 22 '24	Sale	65.00	1,738	112,963	51,923	Jan 23 06:07 PM
Eisele Jeffrey	Chief Development Officer	Jan 22 '24	Sale	65.00	1,607	104,449	65,836	Jan 23 06:05 PM
Deschatelets Pascal	Chief Scientific Officer	Jan 22 '24	Sale	65.00	3,913	254,329	1,118,005	Jan 23 06:03 PM
DeLong Mark Jeffrey	Chief Business & Strat Officer	Jan 22 '24	Sale	65.00	1,384	89,954	65,570	Jan 23 06:01 PM
Chopas James George	VP/Chief Accounting Officer	Jan 22 '24	Sale	65.00	1,061	68,961	39,067	Jan 23 06:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

APLS

Apellis Pharmaceuticals Inc

Upgrade your FINVIZ experience